[Studies on As2O3-induced hyperglycemia (author's transl)]

Area of Science:

• Toxicology
• Endocrinology
• Neuroscience

Background:

• Hyperglycemia, or high blood sugar, is a critical health concern.
• Arsenic trioxide (As2O3) is known to have various toxic effects.
• The specific mechanisms by which As2O3 induces hyperglycemia are not fully understood.

Purpose of the Study:

• To investigate the mechanisms underlying hyperglycemia induced by oral As2O3 administration in rats.
• To determine the role of the central nervous system and adrenal glands in As2O3-induced hyperglycemia.

Main Methods:

• Oral administration of As2O3 (15 mg/kg) to rats.
• Surgical interventions: bilateral splanchnicotomy, adrenalectomy, adrenodemedullation, and bilateral vagotomy.
• Pharmacological interventions: central nervous system depressants (barbital sodium), catecholamine releasers (ephedrine, nicotine), and catecholamine release blockers (hexamethonium, torazoline, propranolol, atropine).
• Measurement of blood glucose levels and hepatic glycogen.

Main Results:

• Peak hyperglycemia occurred 4 hours post-As2O3 administration.
• Hyperglycemia was inhibited by splanchnicotomy, adrenalectomy, and adrenodemedullation, but accelerated by vagotomy.
• Central nervous system depression moderately inhibited hyperglycemia, while drugs affecting catecholamine release/action showed varied effects.
• Hepatic glycogen levels decreased initially and then normalized within 24 hours.

Conclusions:

• As2O3-induced hyperglycemia is mediated through effects on the central nervous system.
• The adrenal glands are involved, but As2O3 does not act directly on them to cause hyperglycemia.
• The findings suggest a complex neuro-endocrine pathway influenced by As2O3.